Y-mAbs Therapeutics (YMAB) Competitors $10.54 -0.32 (-2.95%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends YMAB vs. MRSN, AMRN, HRTX, GBIO, AUPH, CNTA, HRMY, EVO, RXRX, and TARSShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Mersana Therapeutics (MRSN), Amarin (AMRN), Heron Therapeutics (HRTX), Generation Bio (GBIO), Aurinia Pharmaceuticals (AUPH), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Evotec (EVO), Recursion Pharmaceuticals (RXRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "medical" sector. Y-mAbs Therapeutics vs. Mersana Therapeutics Amarin Heron Therapeutics Generation Bio Aurinia Pharmaceuticals Centessa Pharmaceuticals Harmony Biosciences Evotec Recursion Pharmaceuticals Tarsus Pharmaceuticals Mersana Therapeutics (NASDAQ:MRSN) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more volatility and risk, MRSN or YMAB? Mersana Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Do insiders & institutionals have more ownership in MRSN or YMAB? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 11.8% of Mersana Therapeutics shares are held by insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in MRSN or YMAB? Mersana Therapeutics received 119 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 65.87% of users gave Mersana Therapeutics an outperform vote while only 62.50% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes24965.87% Underperform Votes12934.13% Y-mAbs TherapeuticsOutperform Votes13062.50% Underperform Votes7837.50% Is MRSN or YMAB more profitable? Y-mAbs Therapeutics has a net margin of -28.22% compared to Mersana Therapeutics' net margin of -214.20%. Y-mAbs Therapeutics' return on equity of -24.61% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% Y-mAbs Therapeutics -28.22%-24.61%-18.49% Does the media prefer MRSN or YMAB? In the previous week, Mersana Therapeutics had 4 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 18 mentions for Mersana Therapeutics and 14 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 0.62 beat Mersana Therapeutics' score of 0.56 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mersana Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Y-mAbs Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MRSN or YMAB? Mersana Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 170.27%. Y-mAbs Therapeutics has a consensus price target of $21.38, suggesting a potential upside of 102.80%. Given Mersana Therapeutics' higher possible upside, equities analysts plainly believe Mersana Therapeutics is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Y-mAbs Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has higher earnings and valuation, MRSN or YMAB? Y-mAbs Therapeutics has higher revenue and earnings than Mersana Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$36.85M7.44-$171.67M-$0.61-3.64Y-mAbs Therapeutics$84.82M5.57-$21.43M-$0.54-19.52 SummaryY-mAbs Therapeutics beats Mersana Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$486.41M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-19.524.8587.8613.46Price / Sales5.57374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book5.1210.216.946.30Net Income-$21.43M$153.61M$119.12M$225.93M7 Day Performance-9.06%-2.00%-1.84%-1.32%1 Month Performance-27.61%-7.47%-3.65%0.60%1 Year Performance100.38%31.80%31.64%26.23% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics3.3273 of 5 stars$10.54-2.9%$21.38+102.8%+100.8%$486.41M$84.82M-19.52150Analyst ForecastMRSNMersana Therapeutics4.3672 of 5 stars$2.22flat$6.00+170.3%+38.8%$274.24M$36.85M0.00150Analyst RevisionAMRNAmarin0.1111 of 5 stars$0.49flatN/A-37.4%$201.52M$306.91M0.00360Negative NewsHRTXHeron Therapeutics3.9688 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$127.04M0.00300Analyst DowngradeShort Interest ↓GBIOGeneration Bio3.3637 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$92.84M$5.90M0.00150AUPHAurinia Pharmaceuticals1.6876 of 5 stars$8.24+1.4%$10.00+21.4%-10.8%$1.16B$175.51M-54.93300CNTACentessa Pharmaceuticals4.06 of 5 stars$16.74-0.5%$25.83+54.3%+144.7%$1.91B$6.85M0.0072HRMYHarmony Biosciences4.7919 of 5 stars$32.79+1.0%$47.00+43.3%+18.1%$1.85B$582.02M15.54200EVOEvotec1.9292 of 5 stars$5.30+2.9%$5.93+11.9%-49.7%$1.83B$845.74M0.005,061RXRXRecursion Pharmaceuticals1.9971 of 5 stars$6.04-3.7%$9.25+53.1%-12.0%$1.80B$44.58M0.00400Analyst ForecastOptions VolumeHigh Trading VolumeTARSTarsus Pharmaceuticals1.8691 of 5 stars$46.58-0.7%$54.20+16.4%+166.2%$1.79B$17.45M-12.2350Analyst Revision Related Companies and Tools Related Companies MRSN Competitors AMRN Competitors HRTX Competitors GBIO Competitors AUPH Competitors CNTA Competitors HRMY Competitors EVO Competitors RXRX Competitors TARS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:YMAB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts